XOMA Royalty Corporation has successfully acquired all outstanding shares of LAVA Therapeutics N.V., expanding its portfolio in the oncology sector, with shareholders receiving $1.04 per share and contingent value rights.

Target Information

XOMA Royalty Corporation, headquartered in Emeryville, California, has successfully completed the acquisition of LAVA Therapeutics N.V., a biopharmaceutical company known for its innovative approaches in oncology. This acquisition includes all outstanding common shares of LAVA, which has shifted to a new ownership structure under XOMA Royalty. Each LAVA shareholder received a cash payment of $1.04 per share and a non-transferrable contingent value right (CVR), facilitating potential additional payments based on future revenue from LAVA's partnered assets and unpartnered programs.

Through this acquisition, XOMA aims to integrate LAVA's early-stage bispecific antibodies into its growing portfolio, further enhancing its capacity to generate significant long-term value. The strategic partnership with renowned oncology leaders such as Johnson & Johnson and Pfizer adds credibility and opportunity for both companies as they navigate the complexities of drug development and commercialization.

Industry Overview in The Netherlands

The Netherlands possesses a robust biotechnology sector supported by a favorable regulatory environment, advanced research institutions, and a strong network of financing o